The anti-VEGF targeted antibody bevacizumab (BVZ) has been approved for treating renal cell carcinomas (RCCs). Although BVZ increases the progression-free survival of patients with metastatic RCC, the effect on overall survival is poor. To gain insight into the limited efficacy of BVZ on overall survival, we analyzed patient samples of RCC for angiogenic factors that may participate in escape from anti-VEGF therapy. Our study shows that the level of vascular endothelial growth factor (VEGF) in tumors was increased compared with normal tissue. The level of interleukin-8/ CXCL8, a pro-angiogenic member of the CXCL family of cytokines, was also increased in tumors. These observations gave us a good reason to analyze the combined effects of BVZ and anti-CXCL8 antibodies on tumor growth. Surprisingly, we report that BVZ accelerates the growth of RCC in nude mice with in vivo selection of tumor cells with an increased growth capacity. Downregulation of receptor tyrosine phosphatase-j, a phosphatase implicated in EGF receptor regulation, may partly explain this phenomenon. Modification of the vascular network and development of lymphatic vessels through VEGF-C production and compensatory production of pro-angiogenic CXCL cytokines were also observed. The apparent normalization of the vascular network prompted us to associate BVZ with the chemotherapeutic agent paclitaxel. While efficient in vitro, paclitaxel did not reverse the anti-VEGF effects in vivo. Anti-CXCL8-targeting antibodies were promising as they decreased intra-tumor VEGF production; decreased the pro-angiogenic CXCL/anti-angiogenic CXCL ratio and did not induce lymphangiogenesis. These observations hold clinical implication as they highlight putative markers implicated in escape from BVZ treatment. They also recommend proceeding with caution in the use of anti-VEGF therapy alone for treatment of RCC.
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Introduction
Clear cell renal cell carcinomas (RgCC) are vascularized tumors that arise because of mutations in the von Hippel-Lindau gene that cause an overexpression of vascular endothelial growth factor (VEGF). Hence RCC should be one of the most responsive tumors to anti-angiogenic therapy. This hypothesis has stimulated competition in the field of cancer therapy and the development of anti-angiogenic molecules that have obtained approval for treatment of patients with RCC. Bevacizumab (BVZ), a humanized monoclonal antibody targeting VEGF, in association with interferon-a, has obtained FDA approval for treatment (Escudier et al., 2007) . Despite the increased time to progression for all treatments, no enduring efficacy in terms of overall survival has been observed, especially in the pivotal AVOREN study that compared the efficacy of interferon-a versus interferon-a plus BVZ (Escudier et al., 2010) . The defenders of this strategy argue that it is too early to have a global overview of the benefits of the treatment and highlight a real clinical benefit, although this is usually measured in months. The limited effectiveness raises an economic issue, given the high cost of treatment with BVZ. Moreover, some recent papers describe a new phenomenon called treatment evasion and the selection of more aggressive cells with increased metastasis potential in the case of treatment with tyrosine kinase inhibitors targeting tyrosine kinase receptors implicated in angiogenesis (Ebos et al., 2009; Paez-Ribes et al., 2009) . Evasion of treatment could arise through different mechanisms, including angiogenic redundancy (Kerbel, 2008) or inefficacy, owing to the presence of anti-angiogenic forms of VEGF called VEGFxxxb, which result from alternative splicing of the VEGF pre mRNA. XXX corresponds to the number of the amino acid of the protein and includes the forms 121, 145, 165, 189 and 206 (Harper and Bates, 2008) . The pro-angiogenic forms of VEGF will be referred to as VEGFxxx and the anti-angiogenic forms will be referred to as VEGFxxxb in the text.
The aim of our study was to gain insight into the absence of persistent effects of BVZ alone (Yang et al., 2003) . Our hypothesis states that this could be due to the production of redundant angiogenic cytokines. Hence, we have focused on the targeting of VEGF and the cytokines of the CXCL family that have angiogenic and antiangiogenic potency depending on the presence or absence of the amino-acid triplet ELR in their protein sequence (ELR þ CXCL (1, 2, 3, 5, 6, 7, 8) have pro-angiogenic properties, whereas ELRÀCXCL (4, 9, 10) have antiangiogenic properties) (Vandercappellen et al., 2008) , as these cytokines may have prognostic value in breast cancer (Bieche et al., 2007) . ELR þ CXCL stimulate their G-protein-coupled receptors CXCR-1 and CXCR-2, which leads to the activation of the extracellular signalregulated kinase (ERK) pathway (Vandercappellen et al., 2008) . The pro-inflammatory chemokine CXCL8, also referred to as interleukin-8, promotes angiogenesis, tumorigenesis and metastasis. It is overexpressed in many tumors, including RCC (Mestas et al., 2005) . Moreover, the Ras-dependent secretion of CXCL8 enhances tumor progression by promoting neo-vascularization (Sparmann and Bar-Sagi, 2004) . Downregulation of the tumorsuppressor gene, ING4, leads to increased CXCL8 expression but not VEGFxxx expression, which correlated with increased tumor growth and vascular density (Garkavtsev et al., 2004) . Hence, tumor cells may use diverse pro-angiogenic chemokines to mediate angiogenesis and to promote tumor progression. The goal of our study was to highlight new therapeutic targets implicated in anti-angiogenic treatment evasion.
Results

Establishment of an angiogenic profile for human RCC tumors
Cytokines that regulate the angiogenic balance, including members of the CXCL cytokine family, the pro-and anti-angiogenic forms of VEGF (respectively, VEGFxxx and VEGFxxxb, there is no ELISA test recognizing specifically the different forms of VEGFxxx and VEGFxxxb), and factors implicated in the growth of pericytes and lymphatic vessels were measured in normal and tumor samples of clear cell carcinoma samples from 51 patients with RCC. The tumor hemoglobin content served as an indicator of tissue vascularization. An increase in the hemoglobin content in tumor tissues compared with the control was noted (Table 1) . Of the different ELR þ CXCL cytokines investigated only CXCL8 was increased in tumor tissues as compared with the control. VEGFxxx were also more abundant in tumors as compared with control tissue. The ELR þ CXCL cytokines, CXCL3, 5 and 7, were reduced in tumor samples along with PDGFbb and the lymphangiogenic cytokine VEGF-D. VEGFxxxb, CXCL9 and CXCL10 were also decreased significantly.
VEGF blockade accelerates the growth of xenografted RCC cells
We hypothesized that the lack of a persistent effect of BVZ in patients was due to the concomitant presence of VEGF and additional angiogenic cytokines. The results in Table 1 are in favor of this hypothesis particularly for the ELR þ CXCL cytokines as they can induce Abbreviations: RCC, renal cell carcinoma; VEGF, vascular endothelial growth factor. The hemoglobin (Hg) and cytokine levels in samples were measured by a colorimetric assay and ELISA assays, respectively. The intra-tumor levels of Hg and cytokines were compared with normal adjacent tissues (n ¼ 51).
endothelial cell chemotaxis and proliferation (Vandercappellen et al., 2008) . Among ELR þ CXCL, CXCL8 was present in greater amounts in tumor tissues. We observed that different human RCC cells secrete VEGF and CXCL8 ( Figure 1a ). Figure 1b) . BVZ treatment trapped secreted VEGF, as expected, but resulted in increased CXCL8 production. This result suggested production of alternative angiogenic factors by tumor cells. In this context, CXCL8 seemed to be a good candidate to compensate for the loss of VEGF associated with treatment with BVZ. The effect of BVZ on the production of CXCL8 was tested in the different RCC cell lines. Production of CXCL8 does not exceed an upper limit of 0.6 ± 0.1 ng/ml/10 6 cells. If the basal levels are below this limit, BVZ increased the production of CXCL8, which reaches this threshold. If the basal levels are around this threshold, CXCL8 production is equivalent in the presence or absence of BVZ after a short or chronic exposure. Under the same conditions, the levels of VEGF increased with time and BVZ remains effective even after a long time of culture (Supplementary Figure 1) . Nevertheless, of all the ELR þ CXCL, which are equally expressed or more expressed in tumor tissues as compared with normal tissues (CXCL1, 2, 3, 8), CXCL8 remains the most highly produced by the RCC cells. Decreased production of CXCL8 by short-hairpin RNA (sh-RNA) reduces cell proliferation, whereas high doses of CXCL8 stimulate cell proliferation suggesting that an autocrine CXCL8 loop is involved in the proliferation of 786-O cells (Supplementary Figure 2) . These results provided the rationale for testing the impact of blocking VEGF and/or CXCL8 on the development of xenografted tumors. Anti-CXCL7 or anti-CXCL4 was not chosen because they were not produced by RCC cell lines in culture. Anti-CXCL1 was not chosen because the level of CXCL1 was not modified in response to BVZ and the rate of production was low compared with CXCL8 ( Figure 1b and Mestas et al. (2005) ). Thus 786-O LUC þ cells were used to evaluate the incidence of tumor cell growth in vivo following treatment. We noted that BVZ (7.5 mg/kg/ week, a dose corresponding to the amounts adminis- tered to patients) resulted in accelerated tumor growth (Figure 1c ). Mice treated with anti-CXCL8 antibodies (2 mg/kg/week) (Sparmann and Bar-Sagi, 2004) showed growth of tumors equivalent to that in placebo-treated mice. The presence of anti-CXCL8 antibodies partially inhibited the accelerated tumor growth induced by BVZ treatment. As in most preclinical studies the BVZ concentration was twice the amount of that we used, the experiments were repeated with a single or a double BVZ dose. During the first few days after BVZ treatment, we observed a dose-dependent increase in tumor growth (Figure 1d ). These results were not dependent on the cell line, because an equivalent BVZdependent increase in tumor growth was observed with RCC-10 and Caki-2 cells (tumors generated with Caki-2 cells grew very rapidly in the presence of BVZ; Supplementary Figure 3 ).
Decreased tumor blood vessel density but increased tumor lymphatic vessel density in BVZ-treated animals Sections of tumors from all treatment groups were stained for CD31/aSMA and LYVE-1 to study the tumor vasculature and the lymphatic network, respectively ( Figure 2 ). The vessel density and the number of vessels covered with a-smooth muscle actin (aSMA)-labeled cells and their diameters were quantified (Supplementary Figure 4A) . The vascular network (CD31 labeling) was anarchic in placebo-treated tumors. A lower blood vessel density with coverage of vessels with aSMA-labeled cells was observed in BVZ-treated tumors. The effect was more striking if a double dose of BVZ was used, yielding larger vessel lumens and a statistically significant increase in hemoglobin content (mean 334 ± 104 mg/ml/mg protein in control tumors versus 380 ± 189 mg/ml/mg protein for tumors treated with BVZ once a week (P ¼ 0.1); 406±64 mg/ml/mg protein for tumors treated with BVZ twice a week (P ¼ 0.048)). A decrease in vessel density was also observed in anti-CXCL8-treated tumors, with no modification in the intra-tumor hemoglobin content (302 ± 155 mg/ml/mg). However, the number of vessels with aSMA-labeled cell coverage was not modified significantly as compared with the control conditions. Following BVZ plus anti-CXCL8 combined treatment, the total vessel number had a tendency to decrease and the number of vessels covered with aSMA-labeled cells had a tendency to increase, but these modifications were not statistically significant. Nevertheless, the intratumor hemoglobin content was decreased significantly (179±42 mg/ml/mg (P ¼ 0.0012)). Supplementary LYVE-1 labeling, a marker of lymphatic endothelial cells (LECs) (Oliver and Srinivasan, 2010) , was almost nonexistent in control tumors. Following anti-CXCL8 treatment, only a few LYVE-1-labeled cells were observed at the tumor periphery but no signal was detected in the core of the tumors. However, a single or a double BVZ dose induced the accumulation of LYVE-1-labeled cells in the center of tumors (Figure 2b ). BVZ/ anti-CXCL8-treated tumors showed LYVE-1-labeled cells both at the periphery and in the core of tumors. Organization of LYVE-1-labeled cells to putatively formed lumens was also observed following BVZ or anti-CXCL8/BVZ combined treatment but not following anti-CXCL8 treatment alone.
Paclitaxel does not prevent the tumor growth-promoting effects of BVZ RCC are poly-chemo-resistant tumors and only interferon-a increases progression-free survival for approximately 3 months. The results given in Figure 2 prompted us to test the hypothesis of Jain (2005) in which anti-angiogenic therapy normalizes the vascular network, allowing better accessibility of chemotherapeutic agents to tumor cells. Interferon-a treatment gave rise to debilitating side effects in patients and did not alter the production of CXCL cytokines by 786-O cells. Hence, we tested paclitaxel as an alternative chemotherapy in combination with the different anti-angiogenic compounds. As BVZ could have a beneficial effect through vascular normalization, we associated it with a putatively more efficient and tolerable therapeutic agent. The rationale for using paclitaxel is based on the fact that BVZ/paclitaxel treatment has obtained FDA approval for treating metastatic breast cancer and that paclitaxel is better tolerated than interferon-a. 786-O cells were sensitive to paclitaxel (Figure 3a) . CXCL8 was increased with paclitaxel treatment (Figure 3b ), which is probably linked to an increase in CXCL8 gene transcription and CXCL8 mRNA stability (Supplementary Figure 6 ). Such an increase in CXCL8 provided the rationale for testing paclitaxel/BVZ/anti-CXCL8 combined treatment in vivo. Paclitaxel treatment had a modest effect on the growth of 786-O tumors (Figure 3c ). The different antibodies used in combination did not provide any therapeutic advantage. On the contrary, BVZ (7.5 mg/kg once a week) still accelerated tumor growth. The treatment that induced the most aggressive phenotype was BVZ plus paclitaxel. However, anti-CXCL8 still reduced the effect of BVZ on tumor growth. A reduction in the anarchic vessel network was observed with the different treatments (Supplementary Figure 7A) . Whatever the associated treatment, the presence of paclitaxel resulted in a reduction in the blood vessel density, with an increased number of vessels covered with aSMA-labeled cells (Supplementary Figure 4B) . A significant increase in intra-tumor hemoglobin content was observed for the following associations: paclitaxel þ BVZ (473±134 mg/ml/mg (P ¼ 0.05)), paclitaxel þ anti-CXCL8 (704±259 mg/ml/mg (P ¼ 0.003)) and paclitaxel þ BVZ þ anti-CXCL8 (594 ± 122 mg/ml/mg (P ¼ 0.001)), suggesting an increase in tumor perfusion.
Anti-VEGF and/or anti-CXCL8 treatment in combination or not with paclitaxel modifies the tumors' angiogenic profile We have established an impact of anti-VEGF and/or anti-CXCL8 treatment, associated or not with paclitaxel, on the ratio of cytokines of the CXCL and VEGF families. To focus on mechanisms of adaptation to anti-angiogenic therapies in 786-O cells in vivo, we used antibodies specifically recognizing the human forms of these different cytokines. Table 2 summarizes the results of the expression of the different cytokines tested and the level of hemoglobin. BVZ did not significantly modify the amount of intra-tumor VEGFxxx, but BVZ once a week induced a significant increase in the VEGFxxxb isoforms. Anti-VEGF treatment resulted in the compensatory production of CXCL8, as also observed in 786-O cells in vitro (Figure 1b) . BVZ treatment also resulted in the increased production of CXCL1 and 2, whereas it did not affect production in culture conditions (compare Figure 1b and Table 2 ). BVZ decreased CXCL4 and CXCL7 production irrespective of the dose, but only low doses of BVZ increased the production of CXCL10. Anti-CXCL8 decreased the intra-tumor amounts of CXCL8 as expected and modified the angiogenic profile through a decrease in the intra-tumor amounts of CXCL1, 2, 4 and 5, and through an increase in CXCL10. Surprisingly, anti-CXCL8 reduced the intratumor amounts of VEGF. Whereas the double treatment resulted in a decrease in the amount of CXCL1, 2, 4 and 5, and an increase in VEGFxxxb, the amount of intra-tumor VEGF was not modified and CXCL10 was almost undetectable. Increased numbers of lymphatic vessels in BVZ-treated tumors prompted us to test for modification in the levels of VEGF-C and D, the main growth factors implicated in lymphangiogenesis. Whereas the VEGF-D level remained unchanged irrespective of the treatment, an increase in VEGF-C was observed in tumors of treated mice depending on the dose of BVZ. By contrast, VEGF-C levels were lowered by anti-CXCL8 treatment even in the presence of BVZ.
The data show striking differences in the global angiogenic profiles when paclitaxel is associated with anti-angiogenic treatments. Paclitaxel had no major effect on intra-tumor cytokine expression except for inhibition of VEGF-C production. However, major changes were observed when paclitaxel was combined with anti-angiogenic treatments as compared with antiangiogenic treatment alone. Association of BVZ and/or anti-CXCL8 increased the amount of VEGFxxx in the tumors. VEGFxxxb was not affected by the paclitaxel and paclitaxel/BVZ treatments but was decreased by the paclitaxel/anti-CXCL8 treatment and the triple combination. Moreover, when combined with paclitaxel, anti-CXCL8 antibodies no longer change the intra-tumor amount of CXCL1, 2, 4, 8 and 10, and the effects on CXCL5 were modest compared with anti-CXCL8 treatment alone. Surprisingly, CXCL7 was significantly decreased by the paclitaxel/anti-CXCL8 or the paclitaxel/BVZ/anti-CXCL8 combination. The triple treatment almost completely disrupted the tendency to reduce the 'pro-angiogenic factors,' including VEGFxxx, CXCL1 and 2, and to increase the 'anti-angiogenic factors,' including VEGFxxxb. The combination of the three treatments induced the compensatory production of CXCL1, 2 and 8, and the lack of increased production of CXCL10, which is concordant with the increased hemoglobin content of the tumors. Paclitaxel alone or in association with the other treatments reduced VEGF-C production. However, the reduction in VEGF-C production was not associated with a diminished lymphatic vessel number especially when paclitaxel was associated with BVZ or in the triple combination (Supplementary Figure 4B) . This result was not due to the compensatory production of the other lymphangiogenic factor VEGF-D.
Tumor-derived 786-O cells that resist BVZ therapy show an increased growth capacity As BVZ accelerated tumor growth, we hypothesized that tumor cells acquire intrinsic phenotypic properties upon selection pressure in vivo. Hence, we examined Abbreviation: VEGF, vascular endothelial growth factor. The percentage expression of the different cytokines and the hemoglobin (Hg) content of the tumors following treatment are shown. The reference values (100%) correspond to the intra-tumor content of the tumors of PBS-treated mice. Only statistically significant values are shown. Any decrease in Hg, VEGFxxx and ELR þ CXCL is considered to be of good prognosis and is presented on a white background. Any increase in VEGFxxxb or CXCL10 is also considered to be of good prognosis and is also presented on a white background. Conversely, any increase in Hg, VEGFxxx or ELR þ CXCL is considered to be of poor prognosis and is presented on a black background. No change is noted as 'i.d.,' and is given on a gray background. CXCL4 is a marker of poor prognosis if it exceeds a certain threshold in human tumors. Hence, the amount of CXCL4 above the value of control tumors is considered to be a marker of poor prognosis and appears on a black background, whereas the amount below this value is considered to be of good prognosis and appears on a white background.
their proliferation capacity after extraction from tumors. As expected, cells selected from four independent control tumors showed an increased growth capacity when compared with the parental cells. Cells isolated from four independent anti-CXCL8-treated tumors show growth curves almost equivalent to initial cells, whereas cells from four independent double-treated tumors grow like cells from control tumors. Cells isolated from four independent BVZ-treated tumors showed an even more robust growth capacity when compared with cells from vehicle-treated tumors (Figure 4a ). This result indicates that BVZ contributes to the in vivo selection of more aggressive cells with increased growth potential. An Affymetrix screening has revealed that of the 113 differentially expressed genes between cells from control or BVZ-treated tumors, expression of the receptor tyrosine phosphatase-k was reduced significantly (about a factor of 2, confirmed by quantitative reverse transcription-PCR (Po0.01)). This phosphatase is known to decrease the level of phosphorylation of the EGF receptor (EGFR) on a tyrosine residue involved in receptor activity (Tyr-1068) (Xu et al., 2005) . Figure 4b clearly shows that, whereas the levels of EGFR were equivalent in cells from control or BVZ-treated tumors, the phosphorylation levels on Tyr-1068 were significantly upregulated in cells from BVZ-treated tumors. Increased EGFR activity correlates with increased ERK and AKT activities (Figure 4c) , a result, which is consistent with their ability to proliferate faster (Figure 4a) . Whereas a pharmacological inhibitor of the EGFR (erlotinib/Tarceva) (Quatrale et al., 2011) has minor effects on the proliferation of control cells that do not reach statistical significance, it strongly inhibits the proliferation of cells from BVZ-treated tumors, suggesting that these cells have become dependent on this signaling pathway for their growth (Figure 4d ). In order to address the role of autocrine CXCL8 in the proliferation of cells from control or BVZ-treated tumors, cells from two independent control or BVZtreated tumors were transduced with lentivirus expressing a control sh-RNA or an sh-RNA targeting CXCL8 (sh-CXCL8-A used in Supplementary  Figure 2 ). This CXCL8-targeting sh-RNA induced a 90% decrease of CXCL8 production in both cell types. As shown in Figure 4e , whereas sh-CXCL8-A slows down the proliferation of cells from control tumors, it has no effect on cells from BVZ-treated tumors, suggesting that these last cells have acquired independence from CXCL8 for their proliferation after a long-term selection pressure in vivo using BVZ. The amounts of CXCL8 produced by the two cell types are equivalent and could not explain this phenomenon. These results suggest that anti-CXCL8 antibodies cannot inhibit the growth of resistant cells selected during treatment with BVZ.
Discussion
Anti-VEGF therapy leads to decreased tumor growth in models of xenografted cells in nude mice. Such preclinical studies were determinant in authorizing the use of BVZ in association with chemotherapy in different types of human cancers. Surprisingly, FDA approval for use of BVZ for treatment of RCC was given 3 years after approval for colon cancers, although anti-VEGF therapy was in theory designed to treat such tumors. Our results are intriguing as BVZ increases the progression-free survival of patients with RCC when associated with interferon-a (Escudier et al., 2007) . Despite a positive tendency, no improvement in overall survival was described in the pivotal AVOREN study comparing the effect of interferon-a versus interferon-a þ BVZ for the treatment of RCC (Escudier et al., 2010) . We hypothesize that the transient response obtained in patients is related to an initial decrease in tumor burden followed by selection of more aggressive cells. Such transient beneficial effects were not observed in our experiments as the 786-O, RCC-10 or Caki-2 cells had probably undergone selective mechanisms during the laboratory culture conditions that prompted them to react immediately to BVZ. These artificial conditions putatively mimic the progression phase observed by clinicians when patients became refractory to treatment with BVZ. When considering our results we need to remain cautious that they do not undermine the positive effects of BVZ in patients. However, they could help identify markers predictive of no response and reveal possible new therapeutic targets. The mechanisms implicated in BVZ-induced tumor growth are probably numerous and we only highlight some of them. First of all, we did not observe modifications in the intra-tumor amount of human VEGFxxx. ELISA kits recognizing human and mouse VEGF, and ELISA kits specific for human forms produced similar results, which suggests a compensatory increase in the expression of VEGFxxx by 786-O cells in the tumor context.
We also observed a modification in the production of tumor CXCL8, which is considered as marker of breast cancer aggressiveness (Bieche et al., 2007) . Moreover, CXCL8 could indirectly stimulate VEGF production by 786-O cells as they express the CXCR-2 receptor (Mestas et al., 2005) . Stimulation of CXCR-2 induces the activation of the ERK pathway, which could stimulate VEGF gene transcription and increase VEGF mRNA stability (Milanini et al., 1998; Essafi-Benkhadir et al., 2007) .Increased production of CXCL in vitro or in the tumor context following BVZ treatment may be explained by a direct action of VEGFxxx on 786-O cells. This result suggests that RCC cells should express the VEGF receptor(s). The tested RCC cell lines do not express VEGF-R1 and R2 but express neuropilin-1 (Cao et al., 2008) , which may induce cell signaling in response to VEGFxxx. Hence, co-expression of neuropilin-1 and VEGFxxx by RCC cells creates an autocrine loop, which stimulates the phosphatidylinositol-3-OH kinase kinase/AKT pathway (Cao et al., 2008) . Inhibition of this pathway leads to CXCL induction by an unknown mechanism. BVZ could also have a specific action on cells attracted to the tumor microenvironment (Xu et al., 2009) . This assumption was tempting in the case of CXCL4 and 7, which are not produced by 786-O cells in culture. We speculated that cells attracted to the tumor microenvironment secrete signaling molecules that affect the production of cytokines by tumor cells. A decrease in CXCL7 was of good prognosis as it maintains an undifferentiated metanephric mesenchyme and induces cell invasion (Levashova et al., 2007) . A decrease in CXCL4 was a priori, of bad prognosis as it has anti-angiogenic properties. However, its role as a marker of good or bad prognosis varies depending on the tumor type (increased levels suggest good prognosis for hematological tumors (Kim et al., 2008) and bad prognosis for solid tumors (Cervi et al., 2008) ). Our experiments showed that BVZ induced the selection of cells with increased growth capacities, suggesting rapid in vivo selection of aggressive tumor cells following anti-angiogenic treatment (Ebos et al., 2009; Paez-Ribes et al., 2009) . We have determined that cells from BVZtreated tumors have downregulated the expression of receptor tyrosine phosphatase-k, a phosphatase implicated in EGFR activation (Xu et al., 2005) . This result suggests that evasion from BVZ treatment could be related to increased EGFR activation. They could also explain the efficiency of a combination of BVZ with anti-EGFR inhibitors in a phase-I/II trial for RCC (Hainsworth et al., 2007b) , in a phase-II trial for carcinomas of unknown primary site (Hainsworth et al., 2007a) , in phase-I/II trials for squamous cell carcinoma of the head and neck (Cohen et al., 2009) , and in a phase-II clinical trial for the treatment of unresectable biliary cancers (Lubner et al., 2010) . Cascone et al. (2011) have also recently reported an upregulation of stromal EGFR in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
Although the number of patient samples that we tested was small, an increase in the amount of intratumor CXCL8 was observed. Hence, CXCL8 represented an interesting therapeutic target as its inhibition reduced the growth and vascularization of melanoma (Xie, 2001) or ovarian cancers (Merritt et al., 2008) . Anti-CXCL8 antibodies did not reduce the tumor size, but they decreased the production of VEGFxxx, CXCL1 and 8, which are increased in the plasma of RCC patients (Mestas et al., 2005) . Anti-CXCL8 also reduced CXCL4 levels considered as markers of poor prognosis (Cervi et al., 2008) . However, CXCL7 was not affected. The mechanism affecting the differential targeting of CXCL1, 4, 8 and 7 needs to be further investigated. However, Pillai et al. (2006) described that stromal-derived 'activities' were required for optimal expression of CXCL7 by monocytes. We can assume that these 'activities' induce the expression of CXCL7 by tumor cells in vivo. They are not blocked by anti-CXCL8 but by BVZ. The best strategy would be to concomitantly target all of these cytokines or their common receptors CXCR-1 and CXCR-2. An inhibitor of CXCR-1 and CXCR-2, repertaxin, currently in clinical trials for inflammatory diseases, could be more effective than BVZ (Bertini et al., 2004) . The increased amounts of VEGFxxxb following BVZ treatment suggested that it would be more pertinent to target only the proangiogenic members of VEGF. This hypothesis is supported by the presence of the VEGFxxxb isoforms in 70% of the tested tumors. This result could motivate the development of specific antibodies targeting the proangiogenic forms of VEGF. The theory developed by Jain (2005) stipulating that anti-VEGF treatments normalize the vascular network and induce better accessibility to chemotherapeutic agents was appealing and was put forward after the disappointment provoked by the inefficacy of anti-VEGF/CXCL8 therapy. However, our results suggest that Jain's theory is not applicable in this case as paclitaxel, which induces cell death in vitro, was not efficacious in vivo and tumor growth was still observed when combined with BVZ. A significant increase in intra-tumor hemoglobin content and a decrease in intra-tumor carbonic anhydrase-IX were observed in the paclitaxel þ BVZ-treated tumors (Supplementary Figure 8) . These results suggest a normalization of the vascular network and a decrease in tumor hypoxia. However, identical levels of paclitaxel were detected in both tumor types (mean paclitaxel concentrations were 429 ± 64 and 396 ± 52 ng/l, respectively, in tumors after treatment with paclitaxel and paclitaxel plus BVZ (P ¼ 0.535)) suggesting that intratumor delivery of paclitaxel reached a maximum level that cannot be improved by normalization of the vascular network. Different hypotheses could account for the inefficacy of the double treatment: Hypothesis 1: Secretion of signaling molecules into the tumor microenvironment such as CXCL8 (Ginestier et al., 2010) . This hypothesis is supported by the fact that paclitaxel stimulates CXCL8 production at least transiently by a transcriptional and post-transcriptional mechanism ( (Ebos et al., 2009; Paez-Ribes et al., 2009) have shown that anti-angiogenic therapies accelerate tumor dissemination and metastasis. Our results offer a possible explanation for such effects in the context of BVZ treatment as we observed substantial development of the lymphatic network with increased VEGF-C production (Oliver and Srinivasan, 2010) . The increased production of VEGF-C by tumor cells may depend on their stimulation by hyaluronan produced by tumorassociated fibroblasts (Kubota et al., 2009) . LYVE-1-positive cells were still present in the core of the tumor following BVZ/anti-CXCL8 or BVZ/anti-CXCL8/paclitaxel, although VEGF-C was significantly reduced (Figure 2b ; Table 2 and Supplementary Figure 4B ). Under these two conditions, the intra-tumor levels of VEGFxxx are not affected or increased, respectively. This suggests that VEGFxxx could induce lymphangiogenesis only when it reaches a certain threshold (Oliver and Srinivasan, 2010) . Lymphangiogenic growth factors may also be produced by tumor-associated macrophages (Joyce and Pollard, 2009 ) but cannot be detected by our antibodies against the human forms. The presence of cells positive for LYVE-1 in the absence of lymphangiogenic growth factors could also be explained by vascular endothelial cell reprogramming in LECs through Prox-1-dependent expression. Prox-1 is an early-acting instructive factor in mammalian LEC differentiation (Oliver and Srinivasan, 2010) . Simply switching off Prox-1 expression induces a dedifferentiation reprogramming cascade leading to the reacquisition of the vascular endothelial cell status (Oliver and Srinivasan, 2010) . Conversely, interleukin -3 induces Prox-1 expression leading to the LEC differentiation of vascular endothelial cells (Oliver and Srinivasan, 2010) . Thus, cytokines produced in the tumor microenvironment following anti-angiogenic treatments could promote the differentiation of vascular endothelial cells into LECs. Table 3 attempts to score the benefits and adverse effects of the different treatments used in our study. The best score (7) was obtained with anti-CXCL8 treatment, which is consistent with the results of Huang et al. (2010) and Kopetz et al. (2010) , whereas the worst score (À6) was assigned to treatment with BVZ twice weekly or to treatment with paclitaxel/BVZ/anti-CXCL8. Although treatment with anti-CXCL8 is apparently the best, VEGFxxxb and CXCL7, two markers involved in the prognosis of RCC, were not affected by anti-CXCL8 antibodies.
In conclusion, our results should prompt the development of therapies targeting CXCL1, 4, 7 and 8, or VEGF-C. It would be interesting to test their association with BVZ if VEGFxxxb is no longer present or with antibodies specifically targeting the VEGFxxx forms.
Materials and methods
Human kidney samples RCC samples and a normal tissue counterpart were obtained with informed consent from patients after radical nephrectomy. This study analyzed tumors from 51 patients with a median age at diagnosis of 62 years (range: 37-82 years). Two percent of tumors were classified as grade-I, 29% as grade-II, 45% as grade-III and 24% as grade-IV according to Fu¨hrman classification. Thirty-seven percent of the patients deceased less than 2 years after diagnosis. None of the patients were treated with anti-angiogenic drugs.
Cell lines 786-O
LUC þ , RCC-10 LUC þ and Caki-2 LUC þ cells were obtained by lentiviral transduction (pLenti6/V5-D-TOPO; Invitrogen, Villebon sur Yvette, France) and blasticidin selection (10 mg/ml). The concentration of paclitaxel, which reduces tumor cell growth, was assessed by using the 3-[4,5-dimethylthiazol-2yl]-diphenyltetrazolium bromide (MTT) colorimetric assay (Sigma, Lyon, France) according to the manufacturer's instructions.
Antibodies
The following antibodies were used for western blot experiments: Anti-phospho-ERK-1 and 2 antibody (Sigma, St Louis, MO, USA); anti-phospho-Akt, and anti-Akt, EGF receptor and phospho-EGF receptor (Tyr-1068) (Cell Signaling, Cambridge, UK); anti-ERKs and anti-pVHL (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-CAIX (Bayer Health Care, Lyon, France).
Drugs
The anti-human CXCL8 antibody (MAB208; R&D Systems Europe, Lille, France), paclitaxel (Taxol; Bristol-Myers Squibb, Rueil-Malmaison, France) and BVZ (Avastin; 
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Abbreviation: VEGF, vascular endothelial growth factor. A (À) event is considered as a factor that participates in tumor growth, vascularization or dissemination, whereas a ( þ ) event participates in reduced growth, vascularization and dissemination. A ( ¼ ) event is considered as a factor that has no effect. The number of good or bad prognostic markers is shown. Anti-CXCL 8 treatment produced the best score (7) with the highest number of good prognostic indicators (8/14), whereas BVZ twice a week and the paclitaxel/BVZ/anti-CXCL8 combinations produced the worst score (À6). The paclitaxel and paclitaxel/BVZ treatments produced the smallest number of good prognostic markers, and BVZ twice a week and the triple treatments produced the highest number of bad prognostic markers. The white color indicates the best score and the black color the worst score. The gray color indicates intermediate scores.
Roche/Genentech, Indianapolis, IN, USA) were diluted with PBS and injected intra-peritoneally. PBS was injected into the control group. BVZ (7.5 mg/kg) was injected once or twice a week. Anti-human CXCL8 (2 mg/kg) was injected as already described (Sparmann and Bar-Sagi, 2004) . Erlotinib/Tarceva was obtained from Roche (Meylan, France)
Tumor xenograft formation and size evaluation 786-O LUC þ , RCC-10 LUC þ or Caki-2 LUC þ cells (3 Â 10 6 cells) were injected subcutaneously into the flank of 5-week-old nude (nu/nu) female mice (Janvier, Saint Berthevin, France). Bioluminescence was quantified by using an in vivo Imaging System (IVIS; Caliper LifeSciences, Villepinte, France) according to the manufacturer's instructions. Tumor volume was determined in parallel by using a caliper. There was a linear relationship between bioluminescence values and tumor volumes. Tumor fragments were trypsinized overnight at 37 1C and dissociated tumors cells were suspended in the cell culture medium used for 786-O LUC þ cells.
Immunofluorescence experiments
Tumor sections were handled as described previously (Essafi-Benkhadir et al., 2007) . Sections were incubated with anti-mouse LYVE-1 polyclonal (Ab 14817, 1:200; Abcam, Cambridge, MA, USA) or monoclonal anti-a-smooth muscle actin Sigma (A2547, 1:1000; Sigma, France), and rat monoclonal anti-mouse CD31 (clone MEC 13.3, 1:1000; BD Pharmingen, Franklin Lakes, NJ, USA) antibodies. Vessel density and the number of vessels covered by aSMA-labeled cells were evaluated by using the ImageJ program. Several double-blind counts were performed.
Measurement of hemoglobin and cytokines
Frozen tumor tissues were lysed in cell extraction buffer (Biosource, Villebon sur Yvette, Belgium). The intra-tumor hemoglobin content was measured by using the Drabkin reagent kit 525 (Sigma, France). CXCL cytokines, PDGFbb, human and mouse VEGFxxx were measured by using PeproTech ELISA kits according to the manufacturer's recommendations (PeproTech, Neuilly-sur-Seine, France). VEGF-C and VEGFxxxb were measured by using Human DuoSet ELISA kits, and VEGF-D was measured by using the Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA).
Plasmid transfection
The luciferase 3 0 -untranslated region (UTR)-CXCL8 and CXCL8 promoter/luciferase constructs were transfected into 786-O cells with Lipofectamine-2000 (Invitrogen) , according to the manufacturer's recommendations. Four hours after transfection BVZ was added (or not) to the cell culture medium at a concentration of 500 ng/ml. Luciferase assays were performed as described previously (Essafi-Benkhadir et al., 2007) .
Paclitaxel assay in tumors
A 200-mg weight of frozen tumor slice was transferred to a glass tube prior to liquid-liquid extraction with ethyl ether. The supernatants were collected after centrifugation, nitrogendried and analyzed by high-performance liquid chromatography (HPLC)-UV after reconstitution with the mobile phase. The mobile phase consisted of ammonium acetate buffer (32 mM, pH 5) and acetonitrile (53:47, v:v) . Docetaxel was used as an internal standard. The analytes were separated by using a 5-mm, 250 Â 4.6-mm, C18 Nucleosil column (Macherey-Nagel, Hoerdt, France) with a 1.8-ml/min flow rate. Detection was set at 227 nm by using the Alliance HPLC system (Waters, Saint Quentin, France). Statistical analysis was performed by using the Sigma-stat software (Jandel, Erkrath, Germany).
Statistical analysis
Statistical analyses were two-sided and were performed by using R-2.5.0 for Windows. Statistical comparisons were performed by using w 2 -test or Fisher exact test for qualitative data, Student's t-test or Wilcoxon test for quantitative data, and log-rank test for censored data.
